These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33914142)

  • 21. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping.
    Azuma M; Hirai T; Yamada K; Yamashita S; Ando Y; Tateishi M; Iryo Y; Yoneda T; Kitajima M; Wang Y; Yamashita Y
    AJNR Am J Neuroradiol; 2016 May; 37(5):782-8. PubMed ID: 26822728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis.
    Shafieesabet A; Fereshtehnejad SM; Shafieesabet A; Delbari A; Baradaran HR; Postuma RB; Lökk J
    Parkinsonism Relat Disord; 2017 Sep; 42():1-11. PubMed ID: 28647434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
    Saikiran P;
    Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI can detect nigral volume loss in patients with Parkinson's disease: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Parkinsons Dis; 2014; 4(3):405-11. PubMed ID: 24577503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
    Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
    Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimodal assessment of nigrosomal degeneration in Parkinson's disease.
    Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X
    Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substantia nigra fractional anisotropy is not a diagnostic biomarker of Parkinson's disease: A diagnostic performance study and meta-analysis.
    Hirata FCC; Sato JR; Vieira G; Lucato LT; Leite CC; Bor-Seng-Shu E; Pastorello BF; Otaduy MCG; Chaim KT; Campanholo KR; Novaes NP; Melo LM; Gonçalves MR; do Nascimento FBP; Teixeira MJ; Barbosa ER; Amaro E; Cardoso EF
    Eur Radiol; 2017 Jun; 27(6):2640-2648. PubMed ID: 27709279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of iron metabolism markers levels of Parkinson's disease patients determined by fluid and MRI measurements.
    Xu Y; Huang X; Geng X; Wang F
    J Trace Elem Med Biol; 2023 Jul; 78():127190. PubMed ID: 37224790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.
    Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP
    Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substantia nigra nigrosome-1 imaging correlates with the severity of motor symptoms in Parkinson's disease.
    Chu YT; Yu CF; Fan SP; Chen TF; Chiu MJ; Jang JR; Chiu SI; Lin CH
    J Neurol Sci; 2023 Aug; 451():120731. PubMed ID: 37454574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.